AVL-3288

AVL-3288 was developed by researchers at the University of California, Irvine as a selective type I positive allosteric modulator (PAM) of the α7 nicotinic acetylcholine receptor ^[1]. The α7 receptor is heavily expressed in brain regions that support attention and memory and is tied to the sensory-gating deficit, measured as poor suppression of the P50 auditory evoked potential, that is characteristic of schizophrenia ^[1][4]. Because direct α7 agonists had shown early promise but repeatedly failed in longer trials, a PAM approach was pursued in the hope of enhancing signaling without the receptor desensitization that can undermine agonists ^[1][4].

In animal studies, positive allosteric modulation of the α7 receptor with AVL-3288 improved cognitive performance and had effects reaching beyond simple cognition. In a mouse model of autism-like behavior it reduced both impaired sociability and repetitive grooming without impairing movement ^[2], and in a rat model of traumatic brain injury it rescued deficits in learning and memory, restored hippocampal synaptic transmission and long-term potentiation, and reduced hippocampal atrophy when given during the chronic recovery period ^[3]. These findings supported the idea that amplifying endogenous cholinergic signaling through the α7 receptor could aid several conditions marked by cognitive impairment ^[2][3].

AVL-3288 reached human testing. A first-in-human Phase 1 study in healthy volunteers found it safe and well tolerated, with pharmacokinetics that were consistent between subjects and preliminary, though not statistically significant, signs of improved neurocognition and P50 sensory gating ^[1]. A subsequent Phase 1b, placebo-controlled crossover trial in patients with schizophrenia, however, did not demonstrate efficacy: neither cognitive scores nor the P50 biomarker improved relative to placebo, a result in line with the broader disappointment of α7-targeting drugs in this population ^[4]. AVL-3288 remains an investigational compound and is not an approved medicine or a marketed supplement ^[1][4].

AVL-3288 is unusual among research nootropics in that it actually has early human data: it cleared a first-in-human Phase 1 single-ascending-dose study in healthy non-smokers with minimal side effects, consistent pharmacokinetics, and no safety concerns, and a Phase 1b study in schizophrenia patients followed. That is genuinely reassuring for short-term use, but there is still no long-term safety data, and cholinergic side effects (nausea, GI upset) are at least theoretically possible with any compound that boosts acetylcholine signaling. It remains investigational and is not approved for human use, so it sits in research territory rather than as a proven supplement.